Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

ClinicalTrials.gov ID: NCT04596150

Public ClinicalTrials.gov record NCT04596150. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine (CX-2009) in Advanced HR-Positive/HER2-Negative Breast Cancer and of Praluzatamab Ravtansine as Monotherapy and in Combination With Pacmilimab (CX-072) in Advanced Triple-Negative Breast Cancer (CTMX-2009-002)

Study identification

NCT ID
NCT04596150
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
CytomX Therapeutics
Industry
Enrollment
125 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 28, 2020
Primary completion
Jun 1, 2023
Completion
Jun 1, 2023
Last update posted
Jan 22, 2024

2020 – 2023

United States locations

U.S. sites
27
U.S. states
20
U.S. cities
25
Facility City State ZIP Site status
Moores Cancer Center La Jolla California 92093
Los Angeles Hematology Oncology Medical Los Angeles California 90017
USC Norris Cancer Center Los Angeles California 90033
UCLA David Geffen Santa Monica California 90404
Rocky Mountain Cancer Centers Lone Tree Colorado 80124
FCS - South Fort Myers Florida 33901
Baptist Medical Center Jacksonville Florida 32207
Hematology Oncology Assoc of the Treasure Coast Port Saint Lucie Florida 34952
FCS - North St. Petersburg Florida 33705
University of Chicago Medical Center Chicago Illinois 60637
Indiana University Health Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202
Hematology Oncology Clinic Baton Rouge Louisiana 78809
University of Maryland Baltimore Maryland 21201
MGH Boston Massachusetts 02114
DRCI Boston Massachusetts 02215
Allina Health System Minneapolis Minnesota 55407
Nebraska Cancer Specialists Omaha Nebraska 68130
Montefiore Medical Center The Bronx New York 10461
Cleveland Clinic Cleveland Ohio 44195
UPMC Magee-Womens Hospital Pittsburgh Pennsylvania 15213
MUSC Charleston South Carolina 29425
Tennessee Oncology Nashville Tennessee 37203
UT Health East Texas HOPE Cancer Center Tyler Texas 75701
Huntsman Cancer Institute Research Salt Lake City Utah 84112
Virginia Cancer Specialists Fairfax Virginia 22031
Summit Cancer Centers Spokane Washington 99208
University of Wisconsin Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04596150, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 22, 2024 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04596150 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →